# 2026年1月2日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 利用生物工程化病毒在体内实现巨噬细胞的化学遗传性RNA编辑以治疗脓毒症

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476041)
**期刊：** Nature communications
**PMID：** 41476041
**DOI：** 10.1038/s41467-025-67655-y

### 第一部分 原文与翻译

**英文原标题：** In vivo chemogenetic RNA editing of macrophages by bioengineered viruses for sepsis treatment.

> **英文摘要：**
> Sepsis, a life-threatening condition arising from a dysregulated host response to infection, remains a significant clinical challenge with limited therapeutic options. RNA editing presents a promising avenue for modulating gene expression to attenuate the inflammatory cascade characteristic of sepsis. Here, we introduce an approach utilizing chemogenetic activation of CasRx-based RNA editing via bioengineered lentiviruses for the treatment of sepsis. Our strategy involves the targeted delivery of biomineralized lentiviral vectors encoding RNA-editing enzymes and chemogenetic switches to M1 macrophage populations implicated in sepsis pathogenesis. Upon the administration of a small molecule ligand, the chemogenetic switches activate the RNA-editing tool, CasRx, thereby enabling precise and repeated downregulation of NLRP3 mRNA. We demonstrate the efficacy and repeatability of this viral-based approach in mouse models of sepsis, highlighting its potential as a versatile therapeutic strategy for mitigating sepsis-induced inflammation. This study underscores the utility of chemogenetic technologies in harnessing the power of RNA editing for the treatment of sepsis and other inflammatory disorders.

> **中文摘要：**
> 脓毒症是一种由宿主对感染的失调反应引起的危及生命的疾病，仍然是一个具有有限治疗选择的重要临床挑战。RNA编辑为调控基因表达以减轻脓毒症特征性的炎症级联反应提供了一种有前景的途径。在此，我们提出了一种利用生物工程化慢病毒介导的基于CasRx的RNA编辑的化学遗传激活方法，用于治疗脓毒症。我们的策略包括将编码RNA编辑酶和化学遗传开关的生物矿化慢病毒载体靶向递送至参与脓毒症发病机制的M1型巨噬细胞群体。当给予小分子配体时，化学遗传开关激活RNA编辑工具CasRx，从而实现对NLRP3 mRNA的精确且可重复的下调。我们在小鼠脓毒症模型中验证了这种基于病毒的方法的有效性和可重复性，强调了其作为一种多功能治疗策略缓解脓毒症诱导炎症的潜力。本研究突出了化学遗传技术在利用RNA编辑治疗脓毒症及其他炎症性疾病方面的实用价值。

### 第二部分 AI 大师评价

该研究聚焦于一种创新的在体化学遗传调控RNA编辑策略，以靶向巨噬细胞治疗脓毒症。作者通过生物工程化慢病毒递送CasRx系统，并以小分子激活实现特异性下调NLRP3 mRNA，从而减轻炎症反应。动物实验验证了其治疗效果与可重复性，展示了RNA编辑疗法在免疫调控和感染性疾病中的应用前景。研究的最大创新在于将化学遗传激活与RNA编辑结合，为精确调控炎症提供了新的思路，但其在人体应用的安全性与可控性仍需进一步研究。

---

## 2. 内皮细胞中 Endoglin 作为 BMP9 共受体的作用：前肽区置换与 TGFBRII 的募集

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41476036)
**期刊：** Nature communications
**PMID：** 41476036
**DOI：** 10.1038/s41467-025-67531-9

### 第一部分 原文与翻译

**英文原标题：** Endoglin as a BMP9 co-receptor in vascular endothelial cells: prodomain displacement and TGFBRII recruitment.

> **英文摘要：**
> Endoglin (ENG) is a single-pass transmembrane protein highly expressed in vascular endothelial cells (ECs), where it plays fundamental roles in EC functions. ENG is implicated in several cardiovascular disorders including hereditary haemorrhagic telangiectasia, pulmonary arterial hypertension (PAH) and preeclampsia. However, molecular mechanisms underlying ENG function are not fully understood. Initially identified as a co-receptor for TGF-β signalling, ENG's extracellular domain was later found to only bind BMP9 and BMP10 with high affinity. The relationship between these two observations is unclear. Here, we provide evidence for two primary functions of co-receptor ENG. First, ENG efficiently displaces prodomains from BMP9 and BMP10, enabling effective capturing of both ligands from the circulation. Second, ENG binds to and recruits TGFBRII into the BMP9 signalling complex, thereby explaining ENG's involvement in both TGF-β and BMP9 pathways. We identify BMP9 target genes NOG and ADAMTSL2 as preferentially dependent on ENG and show that their transcript levels have strong positive correlation with ENG in human lung tissues; the expression levels of all three genes are significantly reduced in PAH. Our findings address an important gap in our understanding on ENG biology and provide crucial insight for therapeutic targeting these pathways in vascular diseases.

> **中文摘要：**
> Endoglin（ENG）是一种单跨膜蛋白，在血管内皮细胞（ECs）中高表达，并在内皮细胞功能中发挥关键作用。ENG 与多种心血管疾病相关，包括遗传性出血性毛细血管扩张症、肺动脉高压（PAH）和子痫前期。然而，ENG 功能的分子机制尚未完全明了。最初，ENG 被鉴定为 TGF-β 信号通路的共受体，而其胞外结构域后来被发现仅能高亲和力地结合 BMP9 和 BMP10。这两种观察之间的关系仍不清楚。在本研究中，我们提供了 ENG 作为共受体的两个主要功能的证据。首先，ENG 能有效置换 BMP9 和 BMP10 的前肽区，从而促进这两种配体在循环中的高效捕获。其次，ENG 能结合并募集 TGFBRII 至 BMP9 信号复合物内，从而解释了 ENG 同时参与 TGF-β 与 BMP9 通路的机制。我们鉴定出 BMP9 靶基因 NOG 和 ADAMTSL2 对 ENG 的依赖性更高，并显示它们在人体肺组织中的转录水平与 ENG 呈显著正相关；在 PAH 中，这三种基因的表达水平均显著降低。我们的研究填补了对 ENG 生物学理解的重要空白，并为血管疾病中相关通路的治疗干预提供了关键见解。

### 第二部分 AI 大师评价

本研究聚焦于内皮细胞中 Endoglin（ENG）作为 BMP9 共受体的分子机制，揭示其在前肽区置换及 TGFBRII 招募中的功能。作者通过生化和基因表达分析，阐明了 ENG 如何在 TGF-β 与 BMP9 信号通路间建立联系。研究发现 NOG 与 ADAMTSL2 等下游靶基因依赖于 ENG，并在肺动脉高压中显著下调。该工作为理解 ENG 的双重信号调控作用提供了重要机制性证据，对血管疾病的治疗靶向策略具有潜在启示意义。

---

## 3. 接受糖皮质激素及其他免疫调节剂治疗患者的肺部感染

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41475423)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41475423
**DOI：** 10.1055/a-2767-2557

### 第一部分 原文与翻译

**英文原标题：** Pulmonary Infections in Patients Receiving Corticosteroids and Other Immunomodulators.

> **英文摘要：**
> The prevalence of immunosuppression in the general population has been increasing over time due to a combination of factors, including advances in health care and the emergence of new therapies. Population-based studies show that approximately 3% of the population are prescribed systemic corticosteroid therapy at least once a year. Additionally, the number of immunomodulatory agents, such as biologics and small molecules, continues to grow. The chronic use of systemic corticosteroid and immunomodulating agents has an impact not only on the incidence of patients with pneumonia, but also on their microbiology, clinical presentation, and outcomes. Recent cohort studies show that chronic corticosteroid therapy is one of the leading causes of immunosuppression in patients with nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Different immunomodulating agents can have varying effects on the immune system; hence, each agent should be individually analyzed when assessing their impact on the immune system. Important factors to consider are the dose and duration of immunosuppressive medications, as well as their indication. Many of the conditions for which corticosteroids and immunomodulators are prescribed also lead to immunosuppression. In the study, we aim to assess the literature on the risk of pneumonia associated with the use of chronic systemic corticosteroid therapy and immunomodulating agents, particularly biologics and small molecules. We also discuss clinical manifestations and management of patients who develop pneumonia while on these therapies.

> **中文摘要：**
> 由于医疗水平的提高和新治疗方法的出现等多种因素的综合作用，普通人群中免疫抑制的发生率随时间逐渐上升。基于人群的研究显示，大约3%的人群每年至少接受一次全身性糖皮质激素治疗。此外，生物制剂和小分子等免疫调节剂的种类也在持续增加。长期使用全身性糖皮质激素和免疫调节剂不仅影响肺炎患者的发病率，还影响其微生物学特征、临床表现及预后。近期的队列研究表明，慢性糖皮质激素治疗是住院获得性肺炎和需住院治疗的社区获得性肺炎患者免疫抑制的主要原因之一。不同的免疫调节剂对免疫系统的作用可能不同，因此在评估其影响时应对每种药物进行单独分析。需要重点考虑的因素包括免疫抑制药物的剂量、使用时间及其适应证。许多需要使用糖皮质激素和免疫调节剂治疗的疾病本身也会导致免疫抑制。本研究旨在评估既往文献中关于长期系统性糖皮质激素治疗及免疫调节剂（尤其是生物制剂和小分子药物）使用与肺炎风险之间关系的证据，并探讨接受这些治疗后发生肺炎患者的临床表现及管理策略。

### 第二部分 AI 大师评价

该文献综述了长期使用糖皮质激素和免疫调节剂患者的肺部感染风险，重点分析其对肺炎发生率、病原学、临床表现及预后的影响。研究指出，不同免疫调节药物对免疫系统的作用差异显著，需个体化评估其风险。作者从剂量、疗程及适应证等角度系统性梳理了免疫抑制相关因素，并总结临床管理经验。该综述为临床识别和处理免疫抑制相关肺部感染提供了重要参考，但需更多前瞻性研究以验证不同药物类型间的风险差异。

---

速递结束，祝您工作愉快！